Last reviewed · How we verify
DTP-HB-Hib vaccine
This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b pathogens.
This combination vaccine stimulates the immune system to produce antibodies and cellular immunity against diphtheria, tetanus, pertussis, hepatitis B, and Haemophilus influenzae type b pathogens. Used for Prevention of diphtheria, Prevention of tetanus, Prevention of pertussis (whooping cough).
At a glance
| Generic name | DTP-HB-Hib vaccine |
|---|---|
| Also known as | Pentavac |
| Sponsor | Serum Institute of India Pvt. Ltd. |
| Drug class | vaccine |
| Modality | Biologic |
| Therapeutic area | Immunology |
| Phase | FDA-approved |
Mechanism of action
DTP-HB-Hib is a pentavalent inactivated vaccine containing antigens from five pathogens. The diphtheria and tetanus components are toxoids (inactivated bacterial toxins), the pertussis component contains acellular pertussis antigens, the hepatitis B component is recombinant HBsAg, and the Hib component is a polysaccharide conjugate. Together, these antigens trigger both humoral (antibody) and cell-mediated immune responses to provide protection against these five infectious diseases.
Approved indications
- Prevention of diphtheria
- Prevention of tetanus
- Prevention of pertussis (whooping cough)
- Prevention of hepatitis B
- Prevention of Haemophilus influenzae type b infection
Common side effects
- Injection site pain, redness, or swelling
- Fever
- Irritability or fussiness
- Drowsiness
Key clinical trials
- Immunogenicity and Safety of DTP-HB-Hib Using New Hepatitis B Bulk (Bio Farma) (PHASE3)
- Comparison of Immunogenicity and Safety of DTP-HB-Hib (Bio Farma) With Pentabio® Vaccine Primed With Recombinant Hepatitis B (PHASE3)
- Study Comparing DTP-HB-Hib by Disposable-Syringe Jet Injector To Vaccination By Needle And Syringe In Infants (PHASE4)
- Immunogenicity and Safety Profile of Primary Dose of bOPV Bio Farma Given Simultaneously With Pentabio And IPV (PHASE4)
- Antibody Persistence, Immune Response and Safety After Doses of Pentabio Vaccine (PHASE2, PHASE3)
- Protectivity and Safety of DTP/HB/Hib (Bio Farma) Vaccines in Infants, Batch Consistency, Multi Center Trial (PHASE3)
- Immunogenicity and Safety of DTP/HB/Hib (Bio Farma)Compared to DTP/HB Given Simultaneously With Hib(Registered)Vaccine (PHASE2)
- The Safety and Immunogenicity of DTP/Hepatitis B 10ug Hib Vaccine (Bio Farma) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- DTP-HB-Hib vaccine CI brief — competitive landscape report
- DTP-HB-Hib vaccine updates RSS · CI watch RSS
- Serum Institute of India Pvt. Ltd. portfolio CI